Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod in mCRPC
NCT01234311Phase 3Completed
- Sponsor
- Active Biotech AB
- Start
- Mar 2011
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Tasquinimod with Placebo (2 arms). Primary endpoint: Radiographic Progression-Free Survival. Started Mar 2011; status: completed.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01234311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234311.